News
![The Top Stock You Should Consider for Your IRA](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
The Top Stock You Should Consider for Your IRA
If you don't have an individual retirement account (IRA), get one. They provide a great option for accumulating retirement savings on a tax-deferred basis. And with a Roth IRA, you won't have to pay
![10 Reasons Cancer Drugs Usually Cost $100,000 or More a Year](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
10 Reasons Cancer Drugs Usually Cost $100,000 or More a Year
If you've picked up a prescription from your local pharmacy recently, you probably don't need me to tell you that prescription drug prices have handily outpaced wage growth and the rate of inflation
![Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
After boosting its full-year hepatitis C revenue guidance last month, Gilead Sciences' (NASDAQ: GILD) share price has been rallying. However, the Food and Drug Administration approved AbbVie's (NYSE:
![Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is a staple in the portfolios of conservative long-term investors and seniors alike.For decades, J&J, as the company is more commonly known, has
![Celgene vs. Gilead Sciences: Who Reported Better Earnings?](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Celgene vs. Gilead Sciences: Who Reported Better Earnings?
Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) reported second-quarter earnings that were better than industry-watchers' forecasts, but these two giants' circumstances are very
![Quintiles IMS Holdings Continues to Execute](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Quintiles IMS Holdings Continues to Execute
Quintiles IMS Holdings (NYSE: Q), a leading service provider to the healthcare and life sciences industries, reported its second-quarter results on Aug. 3. While year-over-year comparisons continue to
![Exelixis, Inc. Grows Revenue, Eyes Treating More Patients](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Exelixis, Inc. Grows Revenue, Eyes Treating More Patients
Sales of Exelixis' (NASDAQ: EXEL) kidney cancer drug Cabometyx continued to grow at a torrid pace in the second quarter, allowing the company to post another profitable quarter.MetricQ2 2017Continue
![AstraZeneca plc: Buy the Dip?](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
AstraZeneca plc: Buy the Dip?
AstraZeneca plc (NYSE: AZN) stock tumbled after the company announced the failure of an important clinical trial recently. Although the shares have recovered somewhat, the stock is still off by about
![Why Vertex Pharmaceuticals Skyrocketed 17.8% in July](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Why Vertex Pharmaceuticals Skyrocketed 17.8% in July
After reporting results from mid-stage trials showing its multi-drug combination therapies improved lung function in cystic fibrosis patients, Vertex Pharmaceuticals (NASDAQ: VRTX) shares surged 17.8%
![3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance
Any way you look at, Exelixis (NASDAQ: EXEL) just reported an impressive second-quarter performance. The biotech posted its second quarter of profitability, with earnings topping Wall Street
![A Large-Scale Acquisition Is Unlikely for Pfizer Until This Happens](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
A Large-Scale Acquisition Is Unlikely for Pfizer Until This Happens
Pharma titan Pfizer (NYSE: PFE) announced second-quarter earnings on Tuesday, but the drugmaker's performance was clearly a secondary issue for analysts and investors alike. Despite beating consensus
![Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo
Merck & Co (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) are engaged in a battle of sorts. The two won FDA approval for new non-small cell lung cancer therapies in 2015 that work similarly, and
![12 Numbers in Pfizer's Q2 Update More Important Than Its Revenue Decline](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
12 Numbers in Pfizer's Q2 Update More Important Than Its Revenue Decline
Pfizer (NYSE: PFE) announced its second-quarter results before the market opened on Tuesday. And investors yawned -- at least for the most part.Many of the headlines about the big drugmaker's
![2 Dividend-Growth Stocks That Are Minting Money](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
2 Dividend-Growth Stocks That Are Minting Money
If you're looking for a good dividend stock for the long term, it's important to look beyond current dividend yields to the company's prospects for growth and the strength of its free cash flow. A
![Why Clovis Oncology Tumbled 13.5% Today](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Why Clovis Oncology Tumbled 13.5% Today
After disclosing that it's entered into a pact with Bristol-Myers Squibb (NYSE: BMY) on its cancer-fighting drug Rubraca, shares in Clovis Oncology (NASDAQ: CLVS) lost 13.5% of their value Monday.
![Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today
The stock market saw a lot of indecision on Monday, as major benchmarks moved in different directions. The Nasdaq Composite was weaker than most of its peers, but the Dow Jones Industrials jumped to
![A Beat From Qiagen NV, but Only Half a Raise](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
A Beat From Qiagen NV, but Only Half a Raise
It was another solid quarter for Qiagen (NASDAQ: QGEN) as the maker of diagnostic and scientific products continues to post decent revenue growth while getting more efficient, which drives income to
![3 Things You Can Expect With Pfizer's Q2 Results](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
3 Things You Can Expect With Pfizer's Q2 Results
There was good news and bad news for Pfizer (NYSE: PFE) the last time it reported quarterly results. In May, the big drugmaker announced earnings for the first quarter that beat analysts' estimates
![What's Next for AstraZeneca and Its Dividend?](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
What's Next for AstraZeneca and Its Dividend?
Just over three summers ago, AstraZeneca plc (NYSE: AZN) CEO Pascal Soriot convinced shareholders to reject a generous buyout offer from Pfizer with promises that drugs in its pipeline would deliver
![3 Biotech Stocks for Enterprising Investors](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
3 Biotech Stocks for Enterprising Investors
The biotech sector isn't for the faint of heart. While investors can strike it rich if they get lucky, they can also lose a bundle if things don't go according to plan. Given the risk, it can take a
![Celgene Corporation Continues to Get It Done](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Celgene Corporation Continues to Get It Done
Celgene (NASDAQ: CELG) continues to grow revenue with its top-three drugs all experiencing sales growth of at least 20% year over year in the second quarter. The solid quarter allowed management to
![Here's Why NuVasive Is Tanking Today](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Here's Why NuVasive Is Tanking Today
After NuVasive (NASDAQ: NUVA), a medical device maker focused on minimally invasive spine surgery, reported mixed second-quarter earnings results and announced a shake-up in its executive team, its
![3 Value Stocks Senior Citizens Should Consider Buying Today](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
3 Value Stocks Senior Citizens Should Consider Buying Today
News flash, seniors: the average American's life expectancy has increased by roughly a decade since you were born, meaning now more than ever you'll need to ensure you won't outlive your money. This
![Vertex Pharmaceuticals Incorporated Chugs Along](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Vertex Pharmaceuticals Incorporated Chugs Along
Vertex Pharmaceuticals (NASDAQ: VRTX) keeps chugging along, generating increased sales for its two cystic fibrosis drugs as it gains additional approvals to treat more patients, and producing clinical
![Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial
When AstraZeneca (NYSE: AZN) spurned overtures from Pfizer (NYSE: PFE) to combine in one of the biggest merger deals of all time, it told investors not to worry. It had plenty of irons in the fire